Akero Corp (AKRO) Cash per Single Share

Corporate emblem and logo of Akero Therapeutics (AKRO)

The cash per share forecast displayed on the main Akero Therapeutics (AKRO) chart on GURU.Markets shows an indicator value of 8.97. Volatility is driven by the threat of failed trials for the lead drug and a potential collapse in value. The situation is further complicated by a critical dependence on a single product; however, the existence of several research programs in liver metabolism partially mitigates the risks of total failure.

Akero (AKRO): Cash Funds per Share from 07/04/2022 to 12/20/2025

Analytical breakdowns for Akero Therapeutics

- market value and analyst target forecast:
- cash position and cash flow details:
Comprehensive company analysis:AKRO (Akero Therapeutics)
Original product of akerotx.com

For Akero Therapeutics (AKRO), the cash per share chart reflects financial stability during the period leading up to the commercialization of efruxifermin. This metric is calculated as the difference between total cash assets and all liabilities, divided by the number of shares, allowing investors to assess the net liquidity reserve per share available to cover operating expenses and future expansion.